|
Workshop proceedings - Transatlantic workshop on drug-related progressive multifocal leukoencephalopathy (PML)
|
(English only)
|
08/09/2011
|
|
|
Programme - Transatlantic workshop: Drug-related progressive multifocal leukoencephalopathy (PML)
|
(English only)
|
05/04/2011
|
29/07/2011
|
|
Invitation for expressions of interest - Transatlantic workshop: drug-related progressive multifocal leukoencephalopathy (PML)
|
(English only)
|
04/02/2011
|
|
|
List of participants - Transatlantic workshop: Drug-related Progressive Multifocal Leukoencephalopathy (PML)
|
(English only)
|
29/07/2011
|
|
|
Presentation - Welcome, PML - Balancing risks and benefits - the patients' view, Christoph Thalheim
|
(English only)
|
29/07/2011
|
|
|
Presentation - The possible mechanisms of the disease, Eugene Major
|
(English only)
|
29/07/2011
|
|
|
Presentation - The outcomes of drug-induced PML, Joseph Berger
|
(English only)
|
29/07/2011
|
|
|
Presentation - Natalizumab (Tysabri) and PML - the current figures, Brigitte Keller-Stanislawski
|
(English only)
|
29/07/2011
|
|
|
Presentation - The relationship between PML-rituximab and other immunobiologicals: an overview, Renaud Du Pasquier
|
(English only)
|
29/07/2011
|
|
|
Presentation - The risk in transplanted patients, Marco Tuccori
|
(English only)
|
29/07/2011
|
|
|
Presentation - Activities in USA, the experience of FDA Neurology Division, Russel Katz
|
(English only)
|
29/07/2011
|
|
|
Presentation - PML: Risk communication in the EU, Rafe Suvarna
|
(English only)
|
29/07/2011
|
|
|
Presentation - Changes in the incidence of PML in Tysabri-treated patiens, Alice Hughes
|
(English only)
|
29/07/2011
|
|
|
Presentation - A common case definition for PML, Dirk Mentzer
|
(English only)
|
29/07/2011
|
|
|
Presentation - The Italian natalizumab registry, G. Tedeschi
|
(English only)
|
29/07/2011
|
|
|
Presentation - The TYSEDMUS Study, Christian Confavreux
|
(English only)
|
29/07/2011
|
|
|
Presentation - Industry Experience with PML, Carmen Bozic
|
(English only)
|
29/07/2011
|
|
|
Presentation - Development of models for testing possible treatments, Igor Koralnik
|
(English only)
|
29/07/2011
|
|
|
Presentation - Dicovery and development of PML treatments, Teresa Compton
|
(English only)
|
29/07/2011
|
|
|
Presentation - Evidence about plasma exchange in natalizumab related PML, Ralf Gold
|
(English only)
|
29/07/2011
|
|
|
Presentation - Immune Reconstitution Inflammatory Syndrome, Joseph Berger
|
(English only)
|
29/07/2011
|
|
|
Presentation - PML development, Heinz Wiendl
|
(English only)
|
29/07/2011
|
|
|
Presentation - Diagnosing PML, Joseph Berger
|
(English only)
|
29/07/2011
|
|
|
Presentation - Viral subtypes and the development of the disease: what is the evidence, Igor Koralnik
|
(English only)
|
29/07/2011
|
|
|
Presentation - The research in the field: Where to progress?, Eugene Major
|
(English only)
|
29/07/2011
|
|
|
Presentation - Regulators initiative, reserch agenda, Ana Hidalgo
|
(English only)
|
29/07/2011
|
|
|
Presentation - Research Agendas, Eugene Major
|
(English only)
|
29/07/2011
|
|
|
Presentation - The Interface of Academia and Clinical Practice, Joseph Berger
|
(English only)
|
29/07/2011
|
|
|
Presentation - PML consortium - industry, Susan Goelz
|
(English only)
|
29/07/2011
|
|
|
Presentation - Challenges and opportunities from public private partnerships, Richard Bergström
|
(English only)
|
29/07/2011
|
|
|
Presentation - The importance of clarity in relationships and transparency, Henry FItt
|
(English only)
|
29/07/2011
|
|
|
Presentation - Drug Safety Surveillance Initiatives, Gerald Dal Pan
|
(English only)
|
29/07/2011
|
|
|
Presentation - How to facilitate the communicationsdata exchange, Janice Soreth
|
(English only)
|
29/07/2011
|
|
|
Presentation - Public funding of research - EU perspective, Stefanie Prilla
|
(English only)
|
29/07/2011
|
|
|
Presentation - Public funding of research - US, Eugene Major
|
(English only)
|
29/07/2011
|
|
|
Presentation - The role of the pharmaceutical industry, Sophie Banzet
|
(English only)
|
29/07/2011
|
|
|
Presentation - Public Private Partnerships as funders, Hugh Laverty
|
(English only)
|
29/07/2011
|
|
|
Presentation - EU Regulators perspective, Peter Arlett
|
(English only)
|
29/07/2011
|
|
|
Presentation - US Regulators perspective, Russell Katz
|
(English only)
|
29/07/2011
|
|
|
Presentation - Industry PML consortium view, Sophie Banzet
|
(English only)
|
29/07/2011
|
|
|
Presentation - PML London Clinical Researchers perspective, Igor Koralnik
|
(English only)
|
29/07/2011
|
|
|
Presentation - Benefits of Public Health, Eugene Major
|
(English only)
|
29/07/2011
|
|
|
Presentation - Discussion 'progress for the benefit of public health', Ralf Gold
|
(English only)
|
29/07/2011
|
|
|
Presentation - What patients and caregivers want to happen now - priorities for action, Christoph Thalheim
|
(English only)
|
29/07/2011
|
|
|
Presentation - Benefits of Public Health, Eugene Major
|
(English only)
|
29/07/2011
|
|
|
Presentation - PML Final Conclusions, Peter Arlett
|
(English only)
|
29/07/2011
|
|
